| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3204120 | The Journal of Allergy and Clinical Immunology: In Practice | 2014 | 10 Pages |
Abstract
Omalizumab is statistically significantly associated with symptom relief, decreased rescue medication use, and improvement of quality of life in patients with inadequately controlled allergic rhinosinusitis.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sophia MD, PhD, Xanthippi MD, Konstantinos MD, PhD, Evangelia E. MD, PhD,